<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304329</url>
  </required_header>
  <id_info>
    <org_study_id>1245.63</org_study_id>
    <secondary_id>2010-023680-18</secondary_id>
    <nct_id>NCT01304329</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin</brief_title>
  <official_title>Relative Bioavailability of BI 10773 and Simvastatin After Single and Combined Administration - an Open-label, Randomised, Crossover Trial in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the drug-drug interaction potential between BI
      10773 and simvastatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simvastatin: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity. Simvastatin acid is an active metabolite of simvastatin.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empa: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simvastatin: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simvastatin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>treatment A, reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet BI 10773, oral administration with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment B, reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet simvastatin, oral administration with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment C, test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Medium dose oral administration</description>
    <arm_group_label>treatment C, test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Medium dose oral administration</description>
    <arm_group_label>treatment C, test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Medium dose oral administration</description>
    <arm_group_label>treatment B, reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Medium dose oral administration</description>
    <arm_group_label>treatment A, reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - healthy male and female subjects

        Exclusion criteria:

        - Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.63.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.63_Literature.pdf</url>
  </link>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 2, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2011</firstreceived_date>
  <firstreceived_results_date>May 16, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, open label, 3 period crossover study. Treatment periods were separated by a washout period of at least 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empa Alone / Simvastatin Alone / Empa Plus Sim</title>
          <description>Patients were administered three treatments in the following order:
A single dose of empagliflozin 25mg
A single dose of simvastatin 40mg
A single dose of empagliflozin 25mg together with 40mg simvastatin</description>
        </group>
        <group group_id="P2">
          <title>Empa Alone / Empa Plus Sim / Simvastatin Alone</title>
          <description>Patients were administered three treatments in the following order:
A single dose of empagliflozin 25mg
A single dose of empagliflozin 25mg together with 40mg simvastatin
A single dose of simvastatin 40mg</description>
        </group>
        <group group_id="P3">
          <title>Simvastatin Alone / Empa Alone / Empa Plus Sim</title>
          <description>Patients were administered three treatments in the following order:
A single dose of simvastatin 40mg
A single dose of empagliflozin 25mg
A single dose of empagliflozin 25mg together with 40mg simvastatin</description>
        </group>
        <group group_id="P4">
          <title>Simvastatin Alone / Empa Plus Sim / Empa Alone</title>
          <description>Patients were administered three treatments in the following order:
A single dose of simvastatin 40mg
A single dose of empagliflozin 25mg together with 40mg simvastatin
A single dose of empagliflozin 25mg</description>
        </group>
        <group group_id="P5">
          <title>Empa Plus Sim / Empa Alone / Simvastatin Alone</title>
          <description>Patients were administered three treatments in the following order:
A single dose of empagliflozin 25mg together with 40mg simvastatin
A single dose of empagliflozin 25mg
A single dose of simvastatin 40mg</description>
        </group>
        <group group_id="P6">
          <title>Empa Plus Sim / Simvastatin Alone / Empa Alone</title>
          <description>Patients were administered three treatments in the following order:
A single dose of empagliflozin 25mg together with 40mg simvastatin
A single dose of simvastatin 40mg
A single dose of empagliflozin 25mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set: All subjects who took at least 1 dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>This was a randomised, 3-period, crossover trial. The trial was open label. The three treatments were separated by a washout period of at least 7 days.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35.9" spread="8.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>25mg empagliflozin (empa) alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Empa: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
            <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
            <units>nmol*h/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5571.70" spread="5.4"/>
                  <measurement group_id="O2" value="5685.69" spread="5.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Considered characteristic is empa plus simvastatin divided by empa alone</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>102.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.90</ci_lower_limit>
            <ci_upper_limit>105.29</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Simvastatin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity. Simvastatin acid is an active metabolite of simvastatin.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Alone</title>
            <description>40 mg simvastatin alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Simvastatin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
            <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity. Simvastatin acid is an active metabolite of simvastatin.
The geometric mean (gMean) and geometric coefficient of variation (gCV) are adjusted values.</description>
            <units>ng*h/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <sub_title>AUC of simvastatin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.51" spread="40.4"/>
                  <measurement group_id="O2" value="33.93" spread="40.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AUC of simvastatin acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.83" spread="25.5"/>
                  <measurement group_id="O2" value="17.65" spread="25.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC of simvastatin
Considered characteristic is empa plus simvastatin divided by simvastatin alone</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>101.26</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.06</ci_lower_limit>
            <ci_upper_limit>128.07</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC of simvastatin acid
Considered characteristic is empa plus simvastatin divided by simvastatin alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>104.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.09</ci_lower_limit>
            <ci_upper_limit>122.07</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empa: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>25mg empagliflozin (empa) alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Empa: Maximum Measured Concentration (Cmax)</title>
            <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values</description>
            <units>nmol/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="774.06" spread="21.1"/>
                  <measurement group_id="O2" value="847.49" spread="21.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Considered characteristic is empa plus simvastatin divided by empa alone</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>109.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.91</ci_lower_limit>
            <ci_upper_limit>123.69</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Simvastatin: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Alone</title>
            <description>40 mg simvastatin alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Simvastatin: Maximum Measured Concentration (Cmax)</title>
            <description>Maximum measured concentration of the analyte in plasma, per period.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
            <units>ng/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <sub_title>Cmax of simvastatin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.88" spread="41.7"/>
                  <measurement group_id="O2" value="7.65" spread="41.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cmax of simvastatin acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.51" spread="22.7"/>
                  <measurement group_id="O2" value="1.47" spread="22.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of simvastatin.
Considered characteristic is empa plus simvastatin divided by simvastatin alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>97.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.30</ci_lower_limit>
            <ci_upper_limit>123.77</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax of simvastatin acid.
Considered characteristic is empa plus simvastatin divided by simvastatin alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>97.27</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.90</ci_lower_limit>
            <ci_upper_limit>111.44</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>25mg empagliflozin (empa) alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
            <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
            <units>nmol*h/L</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5481.31" spread="5.8"/>
                  <measurement group_id="O2" value="5619.60" spread="5.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Considered characteristic is empa plus simvastatin divided by empa alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>102.52</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.10</ci_lower_limit>
            <ci_upper_limit>106.06</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simvastatin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
        <time_frame>0 hours (h), 20minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) set: PK set included all evaluable subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Alone</title>
            <description>40 mg simvastatin alone</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Sim</title>
            <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Simvastatin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
            <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point.
The geometric mean and geometric coefficient of variation (gCV) are adjusted values.</description>
            <units>ng*h/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <sub_title>AUC of simvastatin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31.82" spread="41.7"/>
                  <measurement group_id="O2" value="32.57" spread="41.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AUC of simvastatin acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.86" spread="24.8"/>
                  <measurement group_id="O2" value="16.53" spread="24.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC of simvastatin.
Considered characteristic is empa plus simvastatin divided by simvastatin alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>102.34</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>41.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.39</ci_lower_limit>
            <ci_upper_limit>130.29</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC of simvastatin acid.
Considered characteristic is empa plus simvastatin divided by simvastatin alone.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>111.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.93</ci_lower_limit>
            <ci_upper_limit>129.02</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration of trial medication until next administration of trial medication or up to post-study visit, up to 36 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empa Alone</title>
          <description>25mg empagliflozin (empa) alone</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin Alone</title>
          <description>40 mg simvastatin alone</description>
        </group>
        <group group_id="E3">
          <title>Empa Plus Sim</title>
          <description>25 mg empagliflozin (empa) together with 40 mg simvastatin (sim)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
